TNONHealthcare · Medical DevicesThe 2 Wall Street analysts covering TENON Medical, Inc. hold a median 12-month price target of $44 — +549.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores TENON Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Issuance (3): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TNON, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +549.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Apr 2025 | Alliance Global Partners | Initiates | Buy | $3.00 |
| 15 Nov 2024 | Maxim Group | Maintains | Buy | — |
| 14 Aug 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 15 Apr 2024 | Benchmark | Maintains | Speculative Buy | — |
| 10 Mar 2023 | Benchmark | Reiterates | Buy | $6.00 |
| 6 Sept 2022 | Benchmark | Initiates | Speculative Buy | — |
| 21 June 2022 | Benchmark | Initiates | Speculative Buy | $6.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNON appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 73% of US stocks
Cheaper than 69% of US stocks
Cheaper than 66% of US stocks
Higher than 95% of US stocks
Higher than 83% of US stocks
Higher than 81% of US stocks
Higher than 10% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 5% of US stocks
Higher than 91% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own TENON Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Tenon Medical, Inc. held its Q2 2026 earnings conference call, during which management discussed the company's financial results and business developments for the quarter.
Why it matters — The earnings call provides investors and analysts with direct insight into Tenon Medical's financial performance and strategic outlook for the period.
Tenon Medical reported Q2 2026 revenue of $1.3 million (up 127% year-over-year) and gross profit of $0.8 million (up 232%), along with FDA 510(k) clearance for its updated Catamaran SI Joint Fusion System and a $4.2 million public offering closed after quarter end.
Why it matters — The significant revenue and gross profit growth, new FDA clearance, and increased training events signal accelerating commercial momentum for Tenon Medical's core product.
Tenon Medical, Inc. announced a 1-for-35 reverse stock split of its issued and outstanding common stock, effective at 12:01 a.m. Eastern Time on August 10, 2026, prior to the start of trading on the Nasdaq Capital Market.
Why it matters — The reverse split will consolidate the company's share count and proportionally increase the per-share stock price, which can affect how TNON shares trade and Nasdaq listing considerations.
Tenon Medical, Inc. announced it will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026, and will host a conference call that same day at 4:30 p.m.
Why it matters — This announcement informs TNON watchers of the upcoming date and time for the company's Q2 2026 earnings release and accompanying conference call.
The 2 Wall Street analysts covering TENON Medical, Inc. have a median 12-month price target of $44, with estimates ranging from $10 to $79. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering TENON Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TENON Medical, Inc. 55 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, TENON Medical, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +549.7% from the last close, and Ticker Nerd's factor model ranks TENON Medical, Inc. 55 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering TENON Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $79 over the next 12 months.
Tenon Medical Inc. operates within the healthcare sector, specifically focusing on the medical device industry.
The most recent item we track (Seeking Alpha, 14 Aug 2026): "Tenon Medical, Inc. (TNON) Q2 2026 Earnings Call Transcript". Tenon Medical, Inc. held its Q2 2026 earnings conference call, during which management discussed the company's financial results and business developments for the quarter.
Tenon Medical Inc. operates within the healthcare sector, specifically focusing on the medical device industry. The company is dedicated to advancing the field of surgical solutions, with its primary emphasis being developing and commercializing products that address unmet clinical needs in the spine surgery market. Tenon Medical Inc.'s most notable innovation is the catheter-based system designed to aid in minimally invasive spinal fusion procedures. This system offers a less invasive approach compared to traditional spine surgeries, potentially reducing recovery times and improving patient outcomes. Serving hospitals, medical centers, and surgical professionals, Tenon Medical Inc. plays a pivotal role in modernizing spine surgery techniques through its advanced technological solutions. By innovating in this niche but crucial area of healthcare, the company contributes to the broader medical technology landscape, encouraging the adoption of less invasive methods that can streamline patient care. As such, Tenon Medical Inc. is integral to the ongoing evolution of surgical practices, reflecting broader trends toward minimally invasive solutions in medical interventions.
CEO Mr. Steven M. Foster · 26 employees · United States · https://www.tenonmed.com